LeonardoFaoroMD

Oncology • South San Francisco, CA

Chief Medical Officer, Quanta Therapeutics

Join to view full profile

Dr. Faoro is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Faoro's full profile

Already have an account?

Office
2 Tower Pl
South San Francisco, CA 94080

Summary

Experienced board-certified medical oncologist and drug developer with more than 15 years of clinical research experience, spanning phase I-IV, with experience filing INDs and BLA/NDAs. Experience in US and Global oncology clinical studies. I have worked on small molecules, and biologics, from signal transduction inhibitors to antibody-drug conjugates and other large molecule constructs.

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2005 - 2009
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2002 - 2005
Federal University of Parana Faculty of MedicineClass of 2001

Clinical Trials

A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE) Start of enrollment: 2005 Sep 01
Completed
Phase 2
A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies Start of enrollment: 2012 Oct 01
Completed
Phase 1
A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors Start of enrollment: 2013 Feb 01
Completed
Phase 1
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy Start of enrollment: 2012 Jan 07
Terminated
Phase 1, Phase 2
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 Start of enrollment: 2015 Jul 16
Completed
Phase 1
A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer Start of enrollment: 2017 Jan 01
Completed
Phase 1
A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2017 May 02
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

8 citations
A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg P...
Jaume Capdevila, Arkadiy Klochikhin, Sophie Leboulleux, Pavel Isaev, Corin Badiu
Thyroid. 2022-05-01
35 citations
A Phase 1a/b Open‑Label, Dose‑Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors.
Niharika B. Mettu, Susanna Varkey Ulahannan, Johanna C. Bendell, Ignacio Garrido-Laguna, John H. Strickler
Clinical Cancer Research. 2021-11-29
106 citations
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Marcia S. Brose, Bruce G. Robinson, Steven I. Sherman, Jolanta Krajewska, Chia-Chi Lin
The Lancet. Oncology. 2021-08-01

Press Mentions

Quanta Therapeutics Appoints Leonardo Faoro, MD, as Chief Medical OfficerDecember 13th, 2022
Quanta Therapeutics Appoints Leonardo Faoro, MD, as Chief Medical OfficerDecember 13th, 2022